Design of clinical trials to evaluate the efficacy of platelet transfusion: The euroSprite trial for components treated with helinx TM technology

Seminars in Hematology

Volumn 38, Issue 4 SUPPL. 11, 2001, Pages 46-54

  Cazenave, Jean Pierre ^a,b,c,d   Davis, Kathryn ^a,b,c,d   Corash, Laurence ^a,b,c,d  

^a ETABLISSEMENT FRANÇAIS DU SANG   (France)

^b UNIVERSITY OF WASHINGTON   (United States)

^c CERUS CORPORATION   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOCYTE CONCENTRATE;

BLEEDING; BLOOD COMPONENT THERAPY; CLINICAL TRIAL; HUMAN; MEDICAL TECHNOLOGY; PRIORITY JOURNAL; REGRESSION ANALYSIS; REVIEW; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; VIRUS INACTIVATION;

EID: 0035189891     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(01)90123-4     Document Type: Article

References (41)

1. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia
2. Causes of death in acute leukemia
3. Acute bleeding after bone marrow transplantation (BMT) - Incidence and effect on survival: A quantitative analysis in 1,402 patients
4. The collection of platelets by apheresisprocedures
5. Platelet production in the Old World - And the New
6. Safety of a stringent prophylactic platelet transfusion policy for patients with acute leukemia
7. Clinical results of a stringent policy on prophylactic platelet transfusion: Non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution
8. The threshold for prophylactic platelet transfusions in adults with acute myelogenous leukemia
9. Safety and cost effectiveness of a 10,000/μL trigger for prophylactic platelet transfusions compared with the traditional 20,000/μL trigger: A prospective comparative trial in 105 patients with acute myeloid leukemia
10. White cell-reduced platelet concentrates prepared by in-line filtration of plateletrich plasma
11. In vitro and in vivo effects of prestorage filtration of apheresis platelets
12. A comparison of prestorage WBC-reduced whole-blood-derived platelets and bedside-filtered whole-blood-derived platelets in autologous progenitor cell transplant
13. Reports of 355 transfusion-associated deaths: 1976 through 1985
14. Storage of platelets in additive solutions: Effects of phosphate
15. S-59 Helinx photochemically treated platelets (plt) are safe and effective for support of thrombocytopenia: Results of the euroSPRITE phase 3 trial
16. Corrected count increments and platelet recoveries as measures of post-transfusion platelet response: Problems and a solution
17. Clinical factors influencing efficacy of pooled platelet transfusions
18. Factors influencing 20-hour increments after platelet transfusion
19. Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation - A prospective analysis
20. Clinical evaluation of the effects of storage time and irradiation on transfused platelets
21. Storage ofapheresis platelets after gamma irradiation
22. Comparison of blood component preparation systems based on buffy coat removal: Component specifications, efficiency, and process costs
23. Platelet transfusion: A dose-response study
24. Clinical consequences of alterations in platelet transfusion dose: A prospective randomized, double-blind trial
25. Platelet transfusion therapy: Consensus conference
26. Platelet transfusions: The 20,000/μL trigger
27. Platelet transfusion therapy: One hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations
28. The selection of compatible platelet donors for refractory patients by lymphocyte HL-A typing
29. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions
30. Factors influencing the response to platelet transfusion
31. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light
32. Post-transfusion viability and tolerability of photochemically treated platelet concentrates (PC)
33. Viability and hemostatic function of photochemically treated (PCT) platelets in thrombocytopenic patients
34. Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function
35. Intercept buffy coat platelets (IPC) are effective during multiple episodes of thrombocytopenia: The euroSPRITE trial
36. Functional characteristics of S- 59 photochemically treated platelet concentrates derived from buffy coats
37. Inactivation of leukocytes in platelet concentrates by psoralen plus UVA
38. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment
39. Platelet transfusions
40. Transfusion results of filtered and subsequently stored random platelet suspensions prepared from buffy coats